Scopus subject area
Best Cancer Research journals
233 Scopus-active journals are ranked in Cancer Research. The top 100 by CiteScore percentile are listed below — 58 of them sit in quartile Q1. Every title links to a full profile with Scopus, Web of Science, ABDC, DOAJ and open-access details.
| # | Journal | CiteScore | Percentile | Quartile | WoS | ABDC | OA |
|---|---|---|---|---|---|---|---|
| 1 | Nature Reviews Cancer | 96.2 | 99th | Q1 | SCIE | – | No |
| 2 | Signal Transduction and Targeted Therapy | 81.6 | 99th | Q1 | SCIE | – | Yes |
| 3 | Cancer Cell | 75.4 | 98th | Q1 | SCIE | – | No |
| 4 | Journal of Hematology and Oncology | 70.1 | 98th | Q1 | SCIE | – | Yes |
| 5 | Molecular Cancer | 55 | 98th | Q1 | SCIE | – | Yes |
| 6 | Seminars in Cancer Biology | 42 | 97th | Q1 | SCIE | – | No |
| 7 | Cancer Communications | 40.3 | 97th | Q1 | SCIE | – | Yes |
| 8 | Nature Cancer | 38.5 | 96th | Q1 | SCIE | – | No |
| 9 | JAMA Oncology | 32.6 | 96th | Q1 | SCIE | – | No |
| 10 | Journal of the National Cancer Center | 31.2 | 95th | Q1 | ESCI | – | Yes |
| 11 | Trends in Cancer | 30.8 | 95th | Q1 | SCIE | – | No |
| 12 | Drug Resistance Updates | 29.1 | 95th | Q1 | SCIE | – | No |
| 13 | Journal of Experimental and Clinical Cancer Research | 22.3 | 94th | Q1 | SCIE | – | Yes |
| 14 | Neuro-Oncology | 21.1 | 94th | Q1 | SCIE | – | No |
| 15 | Experimental Hematology and Oncology | 19.6 | 93th | Q1 | SCIE | – | Yes |
| 16 | Leukemia | 19.2 | 93th | Q1 | SCIE | – | No |
| 17 | Cell Death and Disease | 17.6 | 92th | Q1 | SCIE | – | Yes |
| 18 | Clinical Cancer Research | 17.3 | 92th | Q1 | SCIE | – | No |
| 19 | Cancer Research | 17 | 92th | Q1 | SCIE | – | No |
| 20 | Journal for ImmunoTherapy of Cancer | 16.6 | 91th | Q1 | SCIE | – | Yes |
| 21 | Cancer and Metastasis Reviews | 16.3 | 91th | Q1 | SCIE | – | No |
| 22 | Cancer Letters | 15.4 | 90th | Q1 | SCIE | – | No |
| 23 | Angiogenesis | 14.3 | 90th | Q1 | SCIE | – | No |
| 24 | Journal of Clinical Oncology | 14.2 | 89th | Q1 | SCIE | – | No |
| 25 | Biochimica et Biophysica Acta - Reviews on Cancer | 14.1 | 89th | Q1 | SCIE | – | No |
| 26 | Oncogene | 14 | 89th | Q1 | SCIE | – | No |
| 27 | Blood Cancer Discovery | 13.9 | 88th | Q1 | ESCI | – | No |
| 28 | British Journal of Cancer | 13.9 | 88th | Q1 | SCIE | – | No |
| 29 | Cell Death Discovery | 13.2 | 87th | Q1 | SCIE | – | Yes |
| 30 | Cancer Immunology Research | 12.6 | 87th | Q1 | SCIE | – | No |
| 31 | Breast | 12.6 | 86th | Q1 | SCIE | – | Yes |
| 32 | Apoptosis | 12.4 | 86th | Q1 | SCIE | – | No |
| 33 | Journal of the National Cancer Institute | 12.3 | 86th | Q1 | SCIE | – | No |
| 34 | ESMO Open | 12 | 85th | Q1 | SCIE | – | Yes |
| 35 | Prostate Cancer and Prostatic Diseases | 11.9 | 85th | Q1 | SCIE | – | No |
| 36 | Gastric Cancer | 11.8 | 84th | Q1 | SCIE | – | No |
| 37 | Annual Review of Biomedical Data Science | 11.6 | 84th | Q1 | SCIE | – | No |
| 38 | Cancer Biology and Medicine | 11.5 | 83th | Q1 | SCIE | – | Yes |
| 39 | Neoplasia (United States) | 11.4 | 83th | Q1 | SCIE | – | Yes |
| 40 | Cancer Gene Therapy | 11.1 | 83th | Q1 | SCIE | – | No |
| 41 | Oncogenesis | 11 | 82th | Q1 | SCIE | – | Yes |
| 42 | European Journal of Cancer | 10.9 | 82th | Q1 | SCIE | – | No |
| 43 | Cancer | 10.6 | 81th | Q1 | SCIE | – | No |
| 44 | Cancer Cell International | 10.5 | 81th | Q1 | SCIE | – | Yes |
| 45 | Tumour Virus Research | 10.5 | 80th | Q1 | ESCI | – | Yes |
| 46 | Cancer Drug Resistance | 10.3 | 80th | Q1 | ESCI | – | No |
| 47 | International Journal of Oncology | 10.2 | 80th | Q1 | SCIE | – | No |
| 48 | International Journal of Radiation Oncology Biology Physics | 10.1 | 79th | Q1 | SCIE | – | No |
| 49 | Annual Review of Cancer Biology | 10 | 79th | Q1 | SCIE | – | No |
| 50 | npj Precision Oncology | 9.8 | 78th | Q1 | SCIE | – | Yes |
| 51 | International Journal of Cancer | 9.7 | 78th | Q1 | SCIE | – | No |
| 52 | Molecular Cancer Research | 9.6 | 77th | Q1 | SCIE | – | No |
| 53 | Molecular Therapy Oncology | 9.6 | 77th | Q1 | SCIE | – | Yes |
| 54 | Stem Cell Reviews and Reports | 9.6 | 77th | Q1 | SCIE | – | No |
| 55 | Cancer Immunology, Immunotherapy | 9.5 | 76th | Q1 | SCIE | – | Yes |
| 56 | Molecular Cancer Therapeutics | 9.5 | 76th | Q1 | SCIE | – | No |
| 57 | Molecular Oncology | 9.4 | 75th | Q1 | SCIE | – | Yes |
| 58 | Cancers | 9 | 75th | Q1 | SCIE | – | Yes |
| 59 | Cancer Science | 8.9 | 74th | Q2 | SCIE | – | Yes |
| 60 | Cellular Oncology | 8.6 | 74th | Q2 | SCIE | – | Yes |
| 61 | Cancer Biology and Therapy | 8.4 | 74th | Q2 | SCIE | – | Yes |
| 62 | Advances in Cancer Biology - Metastasis | 8.1 | 73th | Q2 | ESCI | – | Yes |
| 63 | Breast Cancer Research | 8.1 | 73th | Q2 | SCIE | – | Yes |
| 64 | Chinese Journal of Cancer Research | 7.9 | 72th | Q2 | SCIE | – | No |
| 65 | Journal of Gastric Cancer | 7.8 | 72th | Q2 | SCIE | – | No |
| 66 | Cancer Research and Treatment | 7.7 | 71th | Q2 | SCIE | – | Yes |
| 67 | Oncology Reports | 7.7 | 71th | Q2 | SCIE | – | No |
| 68 | Lung Cancer | 7.4 | 71th | Q2 | SCIE | – | No |
| 69 | Clinical and Experimental Metastasis | 7.4 | 70th | Q2 | SCIE | – | No |
| 70 | Epigenetics | 7.4 | 70th | Q2 | SCIE | – | Yes |
| 71 | Genes and Cancer | 7.3 | 69th | Q2 | – | – | No |
| 72 | Translational Oncology | 7.3 | 69th | Q2 | SCIE | – | Yes |
| 73 | Molecular Medicine Reports | 7.3 | 68th | Q2 | SCIE | – | No |
| 74 | Endocrine-Related Cancer | 7.2 | 68th | Q2 | SCIE | – | No |
| 75 | Advances in Cancer Research | 7 | 68th | Q2 | – | – | No |
| 76 | Targeted Oncology | 6.9 | 67th | Q2 | SCIE | – | No |
| 77 | Oncologist | 6.8 | 67th | Q2 | SCIE | – | Yes |
| 78 | Anti-Cancer Agents in Medicinal Chemistry | 6.7 | 66th | Q2 | SCIE | – | No |
| 79 | Frontiers in Oncology | 6.6 | 66th | Q2 | SCIE | – | Yes |
| 80 | Current Hematologic Malignancy Reports | 6.6 | 65th | Q2 | SCIE | – | No |
| 81 | Nitric Oxide - Biology and Chemistry | 6.6 | 65th | Q2 | SCIE | – | No |
| 82 | PLOS Genetics | 6.6 | 65th | Q2 | SCIE | – | Yes |
| 83 | Journal of Mammary Gland Biology and Neoplasia | 6.5 | 64th | Q2 | SCIE | – | No |
| 84 | Oral Oncology | 6.5 | 64th | Q2 | SCIE | – | No |
| 85 | Cytotherapy | 6.4 | 63th | Q2 | SCIE | – | No |
| 86 | Seminars in Radiation Oncology | 6.4 | 63th | Q2 | SCIE | – | No |
| 87 | Journal of Cancer Research and Clinical Oncology | 6.4 | 62th | Q2 | SCIE | – | Yes |
| 88 | Cancer Pathogenesis and Therapy | 6.2 | 62th | Q2 | ESCI | – | Yes |
| 89 | Clinical Lung Cancer | 6.2 | 62th | Q2 | SCIE | – | No |
| 90 | Nutrition and Cancer | 6.2 | 61th | Q2 | SCIE | – | No |
| 91 | Virus Research | 6.2 | 61th | Q2 | SCIE | – | Yes |
| 92 | JCO Precision Oncology | 6.2 | 60th | Q2 | SCIE | – | No |
| 93 | Cancer Cytopathology | 6.1 | 60th | Q2 | SCIE | – | No |
| 94 | Breast Cancer Research and Treatment | 6.1 | 59th | Q2 | SCIE | – | No |
| 95 | Carcinogenesis | 6.1 | 59th | Q2 | SCIE | – | No |
| 96 | JNCI Cancer Spectrum | 6 | 59th | Q2 | ESCI | – | Yes |
| 97 | Genes Chromosomes and Cancer | 6 | 58th | Q2 | SCIE | – | No |
| 98 | NAR Cancer | 5.9 | 58th | Q2 | ESCI | – | Yes |
| 99 | Cancer Biotherapy and Radiopharmaceuticals | 5.9 | 57th | Q2 | SCIE | – | No |
| 100 | Medical Oncology | 5.9 | 57th | Q2 | SCIE | – | No |
Rank and percentile are within the Cancer Research Scopus subject table (CiteScore 2025, dataset 2026-06-09). A journal can rank differently in its other subject areas — open its profile for the full picture.